Oligonucleotides Derived From Mycobacterium for Stimulating Immune Function, Treating Immune-Related Diseases, Atopic Dermatitis and/or Protecting Normal Immune Cell

• US 20080249291A1
• Filed: 01/28/2005
• Published: 10/09/2008
• Est. Priority Date: 01/28/2005
• Status: Active Grant

• Current Assignee: Hyung-Joo Kwon, Tae-Yoon Kim
• Original Assignee: Hyung-Joo Kwon, Tae-Yoon Kim
• Inventors: Kwon, Hyung-Joo, Kim, Tae-Yoon, Kim, Doo-Sik
• Granted Patent: US 7,902,161 B2
• Time in Patent Office: Days
• US Class Current: 536/23.1
• CPC Class Codes: A61K 2039/55561 CpG containing adjuvants; Oligonucleotide containing adjuvants
• CPC Class Codes: A61K 2039/57 characterised by the type of response, e.g. Th1, Th2
• CPC Class Codes: A61P 17/00 Drugs for dermatological disorders
• CPC Class Codes: A61P 37/00 Drugs for immunological or allergic disorders
• CPC Class Codes: A61P 37/04 Immunostimulants
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: C07H 21/00 Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids

Abstract

Disclosed are oligonucleotides for manipulating an immune reaction. The oligonucleotides of the present invention may be useful to stimulate the immune function, to treat the immune-related diseases and the atopic dermatitis, or to protect the normal immune cells.

Claims

1. Oligodeoxynucleotides for stimulating an adjuvant or treating immune-related diseases, presented in General Formula:

[General Formula];

HKCGTTCRTGTCSGM 

 

(SEQ ID NO;

     1)

wherein, R represents A or G;

S represents C or G;

H represents A, T or C;

K represents G or T; and

M represents C or A.

2. The oligodeoxynucleotides for stimulating an adjuvant or treating immune-related diseases according to the claim 1,

wherein the oligonucleotides further comprise five nucleotides, presented in following General Formula, at a 5′

-terminal end and a 3′

-terminal end;

[General Formula];

DKMHKCGTTCRTGTCSGMYK 

 

(SEQ ID NO;

     2)

wherein, R represents A or G;

S represents C or G;

H represents A, T or C;

K represents G or T;

D represents A, G or T;

M represents C or A;

M represents C or A; and

Y represents C or T.

3. The oligodeoxynucleotides according to any of the claims 1 and 2,

wherein the oligodeoxynucleotides protect normal immune cells when the radiotherapy is applied.

4. The oligodeoxynucleotides according to any of the claims 1 and 2,

wherein the oligodeoxynucleotides treat or prevent skin diseases.

5. The oligodeoxynucleotides according to any of the claims 1 and 2,

wherein the oligodeoxynucleotides maintain balances of various Th1/Th2 immune reactions.

6. The oligodeoxynucleotides according to any of the claims 1 and 2,

wherein the oligodeoxynucleotides have a phosphodiester bond or phosphorothioate bond between the nucleotides.

7. The oligodeoxynucleotides according to any of the claims 1 and 2,

wherein the oligonucleotides are selected from the group consisting of 5′

-AGCAGCGTTCGTGTCGGCCT-3′

(SEQ ID NO;

     3), 5′

-AGCAGCGTTCGTGTGCGCCT-3′

(SEQ ID NO;

     4), 5′

-AGCAGCGTTCATGTCGGCCT-3′

(SEQ ID NO;

     5), 5′

-AGCAGCGTTCGTGTCCGCCT-3′

(SEQ ID NO;

     6), 5′

-GTATTCGTTCGTGTCGTCCT-3′

(SEQ ID NO;

     7) and 5′

-TGACTCGTTCGTGTCGCATG-3′

(SEQ ID NO;

     8).